BVF PARTNERS L P/IL has filed 129 insider transactions across 13 companies since January 2023.
Most recent transaction: a sale of 248530 shares of MoonLake Immunotherapeutics ($MLTX) on March 31, 2026.
Activity breakdown: 48 open-market purchases and 18 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | MoonLake Immunotherapeutics | $MLTX | BVF PARTNERS L P/IL | Director | S | Class A Ordinary Shares, $0.0001 par value | 248530 | $16.79 | 1,039,238.0000 | 64,037,478 | 19.30% | 0.39% |
| March 31, 2026 | MoonLake Immunotherapeutics | $MLTX | BVF PARTNERS L P/IL | Director | S | Class A Ordinary Shares, $0.0001 par value | 1569116 | $16.79 | 6,599,722.0000 | 64,037,478 | 19.21% | 2.45% |
| March 31, 2026 | MoonLake Immunotherapeutics | $MLTX | BVF PARTNERS L P/IL | Director | S | Class A Ordinary Shares, $0.0001 par value | 1932354 | $16.79 | 8,302,735.0000 | 64,037,478 | 18.88% | 3.02% |
| Jan. 28, 2026 | Repare Therapeutics Inc. | $RPTX | BVF PARTNERS L P/IL | TenPercentOwner | U | Common Shares, no par value | 5309432 | $0.00 | 0.0000 | 43,051,934 | 100.00% | 12.33% |
| Jan. 28, 2026 | Repare Therapeutics Inc. | $RPTX | BVF PARTNERS L P/IL | TenPercentOwner | U | Common Shares, no par value | 548938 | $0.00 | 0.0000 | 43,051,934 | 100.00% | 1.28% |
| Jan. 28, 2026 | Repare Therapeutics Inc. | $RPTX | BVF PARTNERS L P/IL | TenPercentOwner | U | Common Shares, no par value | 4308573 | $0.00 | 0.0000 | 43,051,934 | 100.00% | 10.01% |
| Oct. 9, 2025 | ESSA Pharma Inc. | $EPIX | BVF PARTNERS L P/IL | TenPercentOwner | U | Common Stock | 4726743 | $0.00 | 0.0000 | 44,388,550 | 100.00% | 10.65% |
| Oct. 9, 2025 | ESSA Pharma Inc. | $EPIX | BVF PARTNERS L P/IL | TenPercentOwner | U | Common Stock | 560797 | $0.00 | 0.0000 | 44,388,550 | 100.00% | 1.26% |
| Oct. 9, 2025 | ESSA Pharma Inc. | $EPIX | BVF PARTNERS L P/IL | TenPercentOwner | U | Common Stock | 6194145 | $0.00 | 0.0000 | 44,388,550 | 100.00% | 13.95% |
| Aug. 5, 2025 | ESSA Pharma Inc. | $EPIX | BVF PARTNERS L P/IL | TenPercentOwner | S | Common Stock | 66 | $1.88 | 4,726,743.0000 | 44,388,550 | 0.00% | 0.00% |
| Aug. 5, 2025 | ESSA Pharma Inc. | $EPIX | BVF PARTNERS L P/IL | TenPercentOwner | X | Pre-funded Warrants | 203336 | $0.00 | 0.0000 | 44,388,550 | 100.00% | 0.46% |
| Aug. 5, 2025 | ESSA Pharma Inc. | $EPIX | BVF PARTNERS L P/IL | TenPercentOwner | X | Pre-funded Warrants | 1235030 | $0.00 | 0.0000 | 44,388,550 | 100.00% | 2.78% |
| Aug. 5, 2025 | ESSA Pharma Inc. | $EPIX | BVF PARTNERS L P/IL | TenPercentOwner | X | Pre-funded Warrants | 1481634 | $0.00 | 0.0000 | 44,388,550 | 100.00% | 3.34% |
| Aug. 5, 2025 | ESSA Pharma Inc. | $EPIX | BVF PARTNERS L P/IL | TenPercentOwner | S | Common Stock | 11 | $1.88 | 560,797.0000 | 44,388,550 | 0.00% | 0.00% |
| Aug. 5, 2025 | ESSA Pharma Inc. | $EPIX | BVF PARTNERS L P/IL | TenPercentOwner | X | Common Stock | 1481634 | $0.00 | 6,194,224.0000 | 44,388,550 | 31.44% | 3.34% |
| Aug. 5, 2025 | ESSA Pharma Inc. | $EPIX | BVF PARTNERS L P/IL | TenPercentOwner | X | Common Stock | 1235030 | $0.00 | 4,726,809.0000 | 44,388,550 | 35.37% | 2.78% |
| Aug. 5, 2025 | ESSA Pharma Inc. | $EPIX | BVF PARTNERS L P/IL | TenPercentOwner | X | Common Stock | 203336 | $0.00 | 560,808.0000 | 44,388,550 | 56.88% | 0.46% |
| Aug. 5, 2025 | ESSA Pharma Inc. | $EPIX | BVF PARTNERS L P/IL | TenPercentOwner | S | Common Stock | 79 | $1.88 | 6,194,145.0000 | 44,388,550 | 0.00% | 0.00% |
| June 30, 2025 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Common Stock, $0.0001 par value | 58780 | $44.00 | 353,412.0000 | 75,043,991 | 19.95% | 0.08% |
| June 30, 2025 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Common Stock, $0.0001 par value | 142604 | $44.00 | 2,798,795.0000 | 75,043,991 | 5.37% | 0.19% |
| June 30, 2025 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Common Stock, $0.0001 par value | 115783 | $44.00 | 2,219,858.0000 | 75,043,991 | 5.50% | 0.15% |
| June 25, 2025 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | A | Stock Option (Right to Buy) | 16000 | $0.00 | 116,190.0000 | 75,043,991 | 15.97% | 0.02% |
| June 13, 2025 | CRESCENT BIOPHARMA, INC. | $CBIO | BVF PARTNERS L P/IL | TenPercentOwner | J | Common Stock | 56079 | $0.00 | 62,383.0000 | 0 | 889.58% | 0.00% |
| June 13, 2025 | CRESCENT BIOPHARMA, INC. | $CBIO | BVF PARTNERS L P/IL | TenPercentOwner | J | Pre-Funded Warrants to Purchase Common Stock | 257515 | $0.00 | 257,515.0000 | 0 | 9999.99% | 0.00% |
| June 13, 2025 | CRESCENT BIOPHARMA, INC. | $CBIO | BVF PARTNERS L P/IL | TenPercentOwner | J | Pre-Funded Warrants to Purchase Common Stock | 25944 | $0.00 | 25,944.0000 | 0 | 9999.99% | 0.00% |
| June 13, 2025 | CRESCENT BIOPHARMA, INC. | $CBIO | BVF PARTNERS L P/IL | TenPercentOwner | J | Common Stock | 556617 | $0.00 | 593,740.0000 | 0 | 1499.39% | 0.00% |
| June 13, 2025 | CRESCENT BIOPHARMA, INC. | $CBIO | BVF PARTNERS L P/IL | TenPercentOwner | J | Pre-Funded Warrants to Purchase Common Stock | 304098 | $0.00 | 304,098.0000 | 0 | 9999.99% | 0.00% |
| June 13, 2025 | CRESCENT BIOPHARMA, INC. | $CBIO | BVF PARTNERS L P/IL | TenPercentOwner | J | Common Stock | 657308 | $0.00 | 707,116.0000 | 0 | 1319.68% | 0.00% |
| June 11, 2025 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Other | A | Stock Option (Right to buy) | 24150 | $0.00 | 176,270.0000 | 58,743,522 | 15.88% | 0.04% |
| June 5, 2025 | MoonLake Immunotherapeutics | $MLTX | BVF PARTNERS L P/IL | Director | A | Option to Buy | 6682 | $0.00 | 25,667.0000 | 62,870,237 | 35.20% | 0.01% |
| May 16, 2025 | XOMA Royalty Corp | $XOMA | BVF PARTNERS L P/IL | TenPercentOwner | S | Common Stock, $0.0075 par value per share | 265316 | $27.10 | 1,267,545.0000 | 17,781,000 | 17.31% | 1.49% |
| May 16, 2025 | XOMA Royalty Corp | $XOMA | BVF PARTNERS L P/IL | TenPercentOwner | S | Common Stock, $0.0075 par value per share | 127407 | $27.10 | 1,322,758.0000 | 17,781,000 | 8.79% | 0.72% |
| Jan. 24, 2025 | XOMA Royalty Corp | $XOMA | BVF PARTNERS L P/IL | TenPercentOwner | S | Common Stock, $0.0075 par value per share | 75287 | $26.10 | 0.0000 | 11,701,000 | 100.00% | 0.64% |
| Jan. 24, 2025 | XOMA Royalty Corp | $XOMA | BVF PARTNERS L P/IL | TenPercentOwner | S | Common Stock, $0.0075 par value per share | 339679 | $26.10 | 1,450,165.0000 | 11,701,000 | 18.98% | 2.90% |
| Jan. 24, 2025 | XOMA Royalty Corp | $XOMA | BVF PARTNERS L P/IL | TenPercentOwner | S | Common Stock, $0.0075 par value per share | 85776 | $26.10 | 1,532,861.0000 | 11,701,000 | 5.30% | 0.73% |
| Jan. 24, 2025 | XOMA Royalty Corp | $XOMA | BVF PARTNERS L P/IL | TenPercentOwner | S | Common Stock, $0.0075 par value per share | 149975 | $26.10 | 0.0000 | 11,701,000 | 100.00% | 1.28% |
| Jan. 10, 2025 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Other | D | Common stock, $0.0001 par value | 235450 | $0.00 | 2,755,533.0000 | 58,743,522 | 7.87% | 0.40% |
| Jan. 10, 2025 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Other | D | Common stock, $0.0001 par value | 161810 | $0.00 | 2,103,522.0000 | 58,743,522 | 7.14% | 0.28% |
| Jan. 10, 2025 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Other | A | Pre-Funded Warrant | 235450 | $0.00 | 3,291,004.0000 | 58,743,522 | 7.71% | 0.40% |
| Jan. 10, 2025 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Other | A | Pre-Funded Warrant | 161810 | $0.00 | 2,627,590.0000 | 58,743,522 | 6.56% | 0.28% |
| Jan. 10, 2025 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Other | A | Pre-Funded Warrant | 22740 | $0.00 | 336,288.0000 | 58,743,522 | 7.25% | 0.04% |
| Jan. 10, 2025 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Other | D | Common stock, $0.0001 par value | 22740 | $0.00 | 447,526.0000 | 58,743,522 | 4.84% | 0.04% |
| Dec. 13, 2024 | PALVELLA THERAPEUTICS, INC. | $PVLA | BVF PARTNERS L P/IL | Other | J | Common Stock, $0.001 par value | 174958 | $0.00 | 282,223.0000 | 0 | 163.11% | 0.00% |
| Dec. 13, 2024 | PALVELLA THERAPEUTICS, INC. | $PVLA | BVF PARTNERS L P/IL | Other | J | Common Stock, $0.001 par value | 234323 | $0.00 | 371,916.0000 | 0 | 170.30% | 0.00% |
| Dec. 13, 2024 | PALVELLA THERAPEUTICS, INC. | $PVLA | BVF PARTNERS L P/IL | Other | J | Common Stock, $0.001 par value | 29648 | $0.00 | 38,961.0000 | 0 | 318.35% | 0.00% |
| Dec. 4, 2024 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Other | A | Pre-Funded Warrant | 1258027 | $9.08 | 3,055,554.0000 | 57,262,803 | 69.99% | 2.20% |
| Dec. 4, 2024 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Other | D | Common stock, $0.0001 par value | 1797527 | $0.00 | 2,990,983.0000 | 57,262,803 | 37.54% | 3.14% |
| Dec. 4, 2024 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Other | D | Common stock, $0.0001 par value | 1418736 | $0.00 | 2,265,332.0000 | 57,262,803 | 38.51% | 2.48% |
| Dec. 4, 2024 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Other | D | Common stock, $0.0001 par value | 153441 | $0.00 | 470,266.0000 | 57,262,803 | 24.60% | 0.27% |
| Dec. 4, 2024 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Other | A | Pre-Funded Warrant | 1797527 | $0.00 | 1,797,527.0000 | 57,262,803 | 9999.99% | 3.14% |
| Dec. 4, 2024 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Other | A | Pre-Funded Warrant | 1418736 | $0.00 | 1,418,736.0000 | 57,262,803 | 9999.99% | 2.48% |
| Dec. 4, 2024 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Other | A | Pre-Funded Warrant | 153441 | $0.00 | 153,441.0000 | 57,262,803 | 9999.99% | 0.27% |
| Dec. 4, 2024 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Other | A | Pre-Funded Warrant | 1047044 | $9.08 | 2,465,780.0000 | 57,262,803 | 73.80% | 1.83% |
| Dec. 4, 2024 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Other | A | Pre-Funded Warrant | 160107 | $9.08 | 313,548.0000 | 57,262,803 | 104.34% | 0.28% |
| Nov. 8, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | BVF PARTNERS L P/IL | Other | J | Pre-Funded Warrant | 2378000 | $0.00 | 2,378,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 8, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | BVF PARTNERS L P/IL | Other | J | Common Stock, $0.0001 par value | 240000 | $0.00 | 87,911.0000 | 0 | 73.19% | 0.00% |
| Nov. 8, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | BVF PARTNERS L P/IL | Other | J | Pre-Funded Warrant | 240000 | $0.00 | 240,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 8, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | BVF PARTNERS L P/IL | Other | J | Common Stock, $0.0001 par value | 3062000 | $0.00 | 830,237.0000 | 0 | 78.67% | 0.00% |
| Nov. 8, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | BVF PARTNERS L P/IL | Other | J | Pre-Funded Warrant | 3062000 | $0.00 | 3,062,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 8, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | BVF PARTNERS L P/IL | Other | J | Common Stock, $0.0001 par value | 2378000 | $0.00 | 662,970.0000 | 0 | 78.20% | 0.00% |
| Oct. 29, 2024 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Pre-funded Warrants to Purchase Common Stock | 2213816 | $3.65 | 7,910,445.0000 | 51,945,920 | 38.86% | 4.26% |
| Oct. 29, 2024 | Third Harmonic Bio, Inc. | $THRD | BVF PARTNERS L P/IL | Other | S | Common Stock | 64617 | $14.30 | 176,692.0000 | 0 | 26.78% | 0.00% |
| Oct. 29, 2024 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Pre-funded Warrants to Purchase Common Stock | 440489 | $3.65 | 1,333,356.0000 | 51,945,920 | 49.33% | 0.85% |
| Oct. 29, 2024 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Pre-funded Warrants to Purchase Common Stock | 2100244 | $3.65 | 6,730,394.0000 | 51,945,920 | 45.36% | 4.04% |
| Oct. 29, 2024 | Third Harmonic Bio, Inc. | $THRD | BVF PARTNERS L P/IL | Other | S | Common Stock | 396963 | $14.30 | 1,367,257.0000 | 0 | 22.50% | 0.00% |
| Oct. 29, 2024 | Third Harmonic Bio, Inc. | $THRD | BVF PARTNERS L P/IL | Other | S | Common Stock | 538420 | $14.30 | 1,794,218.0000 | 0 | 23.08% | 0.00% |
| Oct. 4, 2024 | MoonLake Immunotherapeutics | $MLTX | BVF PARTNERS L P/IL | Director | S | Class A Ordinary Shares, $0.0001 par value | 836862 | $50.00 | 8,168,838.0000 | 62,896,782 | 9.29% | 1.33% |
| Oct. 4, 2024 | MoonLake Immunotherapeutics | $MLTX | BVF PARTNERS L P/IL | Director | S | Class A Ordinary Shares, $0.0001 par value | 1030589 | $50.00 | 10,235,089.0000 | 62,896,782 | 9.15% | 1.64% |
| Oct. 4, 2024 | MoonLake Immunotherapeutics | $MLTX | BVF PARTNERS L P/IL | Director | S | Class A Ordinary Shares, $0.0001 par value | 132549 | $50.00 | 1,287,768.0000 | 62,896,782 | 9.33% | 0.21% |
| Aug. 20, 2024 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Pre-Funded Warrants to Purchase Common Stock | 201546 | $40.75 | 1,180,560.0000 | 58,365,499 | 20.59% | 0.35% |
| Aug. 20, 2024 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Pre-Funded Warrants to Purchase Common Stock | 156742 | $40.75 | 1,135,756.0000 | 58,365,499 | 16.01% | 0.27% |
| June 18, 2024 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | A | Stock Option (Right to Buy) | 16000 | $0.00 | 100,190.0000 | 58,365,499 | 19.00% | 0.03% |
| June 14, 2024 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Director | A | Stock Option (Right to buy) | 23000 | $0.00 | 152,120.0000 | 45,247,098 | 17.81% | 0.05% |
| June 6, 2024 | MoonLake Immunotherapeutics | $MLTX | BVF PARTNERS L P/IL | Director | A | Option to Buy | 7688 | $0.00 | 18,985.0000 | 49,122,534 | 68.05% | 0.02% |
| May 9, 2024 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Pre-funded Warrants to Purchase Common Stock | 2526238 | $0.00 | 6,824,745.0000 | 24,619,197 | 58.77% | 10.26% |
| May 9, 2024 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Pre-funded Warrants to Purchase Common Stock | 3173135 | $0.00 | 7,471,642.0000 | 24,619,197 | 73.82% | 12.89% |
| May 9, 2024 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Common Stock, $0.001 par value | 75431 | $0.00 | 220,460.0000 | 24,619,197 | 52.01% | 0.31% |
| May 9, 2024 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Common Stock, $0.001 par value | 821121 | $0.00 | 2,633,679.0000 | 24,619,197 | 45.30% | 3.34% |
| May 9, 2024 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Common Stock, $0.001 par value | 1031385 | $0.00 | 3,361,803.0000 | 24,619,197 | 44.26% | 4.19% |
| May 9, 2024 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Pre-funded Warrants to Purchase Common Stock | 232068 | $0.00 | 4,530,575.0000 | 24,619,197 | 5.40% | 0.94% |
| Jan. 5, 2024 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Pre-Funded Warrants to Purchase Common Stock | 52733 | $25.25 | 52,733.0000 | 58,365,499 | 9999.99% | 0.09% |
| Jan. 5, 2024 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Pre-Funded Warrants to Purchase Common Stock | 375856 | $25.25 | 375,856.0000 | 58,365,499 | 9999.99% | 0.64% |
| Jan. 5, 2024 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Pre-Funded Warrants to Purchase Common Stock | 550425 | $25.25 | 550,425.0000 | 58,365,499 | 9999.99% | 0.94% |
| Nov. 15, 2023 | Repare Therapeutics Inc. | $RPTX | BVF PARTNERS L P/IL | TenPercentOwner | P | Common Shares, no par value | 493337 | $5.00 | 5,155,739.0000 | 0 | 10.58% | 0.00% |
| Nov. 15, 2023 | Repare Therapeutics Inc. | $RPTX | BVF PARTNERS L P/IL | TenPercentOwner | P | Common Shares, no par value | 390507 | $5.00 | 4,182,664.0000 | 0 | 10.30% | 0.00% |
| Nov. 15, 2023 | Repare Therapeutics Inc. | $RPTX | BVF PARTNERS L P/IL | TenPercentOwner | P | Common Shares, no par value | 47712 | $5.00 | 532,795.0000 | 0 | 9.84% | 0.00% |
| Nov. 16, 2023 | Repare Therapeutics Inc. | $RPTX | BVF PARTNERS L P/IL | TenPercentOwner | P | Common Shares, no par value | 153693 | $5.38 | 5,309,432.0000 | 0 | 2.98% | 0.00% |
| Nov. 16, 2023 | Repare Therapeutics Inc. | $RPTX | BVF PARTNERS L P/IL | TenPercentOwner | P | Common Shares, no par value | 125909 | $5.38 | 4,308,573.0000 | 0 | 3.01% | 0.00% |
| Nov. 16, 2023 | Repare Therapeutics Inc. | $RPTX | BVF PARTNERS L P/IL | TenPercentOwner | P | Common Shares, no par value | 16143 | $5.38 | 548,938.0000 | 0 | 3.03% | 0.00% |
| Nov. 3, 2023 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Common Stock, $0.0001 par value | 10106 | $14.07 | 294,632.0000 | 53,933,229 | 3.55% | 0.02% |
| Nov. 2, 2023 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Common Stock, $0.0001 par value | 26772 | $11.64 | 284,526.0000 | 53,933,229 | 10.39% | 0.05% |
| Nov. 3, 2023 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Common Stock, $0.0001 par value | 103885 | $14.07 | 2,656,191.0000 | 53,933,229 | 4.07% | 0.19% |
| Nov. 3, 2023 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Common Stock, $0.0001 par value | 83708 | $14.07 | 2,104,075.0000 | 53,933,229 | 4.14% | 0.16% |
| Nov. 2, 2023 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Common Stock, $0.0001 par value | 57618 | $11.64 | 2,552,306.0000 | 53,933,229 | 2.31% | 0.11% |
| Nov. 2, 2023 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Common Stock, $0.0001 par value | 132016 | $11.64 | 2,020,367.0000 | 53,933,229 | 6.99% | 0.24% |
| Nov. 2, 2023 | Repare Therapeutics Inc. | $RPTX | BVF PARTNERS L P/IL | TenPercentOwner | P | Common Shares, no par value | 492251 | $3.60 | 3,792,157.0000 | 0 | 14.92% | 0.00% |
| Nov. 2, 2023 | Repare Therapeutics Inc. | $RPTX | BVF PARTNERS L P/IL | TenPercentOwner | P | Common Shares, no par value | 72479 | $3.60 | 485,083.0000 | 0 | 17.57% | 0.00% |
| Nov. 2, 2023 | Repare Therapeutics Inc. | $RPTX | BVF PARTNERS L P/IL | TenPercentOwner | P | Common Shares, no par value | 218979 | $3.60 | 4,662,402.0000 | 0 | 4.93% | 0.00% |
| Sept. 12, 2023 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Director | P | Common stock, $0.0001 par value | 677853 | $9.84 | 3,684,068.0000 | 0 | 22.55% | 0.00% |
| Sept. 14, 2023 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Director | J | Common stock, $0.0001 par value | 99556 | $0.00 | 623,707.0000 | 0 | 18.99% | 0.00% |
| Sept. 12, 2023 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Director | P | Common stock, $0.0001 par value | 775278 | $9.84 | 4,788,510.0000 | 0 | 19.32% | 0.00% |
| Sept. 12, 2023 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Director | P | Common stock, $0.0001 par value | 52801 | $9.84 | 623,707.0000 | 0 | 9.25% | 0.00% |
| June 16, 2023 | Olema Pharmaceuticals, Inc. | $OLMA | BVF PARTNERS L P/IL | Director | A | Stock Option (Right to buy) | 21520 | $0.00 | 129,120.0000 | 0 | 20.00% | 0.00% |
| June 15, 2023 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | A | Stock Option (Right to Buy) | 12000 | $0.00 | 84,190.0000 | 53,933,229 | 16.62% | 0.02% |
| May 10, 2023 | Structure Therapeutics Inc. | $GPCR | BVF PARTNERS L P/IL | TenPercentOwner | J | Ordinary Shares, $0.0001 par value per share | 2929660 | $0.00 | 5,173,941.0000 | 71,655,000 | 36.15% | 4.09% |
| May 10, 2023 | Structure Therapeutics Inc. | $GPCR | BVF PARTNERS L P/IL | TenPercentOwner | J | Ordinary Shares, $0.0001 par value per share | 462605 | $0.00 | 5,173,941.0000 | 71,655,000 | 8.21% | 0.65% |
| May 10, 2023 | Structure Therapeutics Inc. | $GPCR | BVF PARTNERS L P/IL | TenPercentOwner | J | Convertible Non-Voting Ordinary Shares | 4018253 | $0.00 | 4,018,253.0000 | 71,655,000 | 9999.99% | 5.61% |
| May 10, 2023 | Structure Therapeutics Inc. | $GPCR | BVF PARTNERS L P/IL | TenPercentOwner | J | Convertible Non-Voting Ordinary Shares | 2929660 | $0.00 | 2,929,660.0000 | 71,655,000 | 9999.99% | 4.09% |
| May 10, 2023 | Structure Therapeutics Inc. | $GPCR | BVF PARTNERS L P/IL | TenPercentOwner | J | Convertible Non-Voting Ordinary Shares | 462605 | $0.00 | 462,605.0000 | 71,655,000 | 9999.99% | 0.65% |
| May 10, 2023 | Structure Therapeutics Inc. | $GPCR | BVF PARTNERS L P/IL | TenPercentOwner | J | Ordinary Shares, $0.0001 par value per share | 4018253 | $0.00 | 5,173,941.0000 | 71,655,000 | 43.71% | 5.61% |
| May 5, 2023 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Common Stock, $0.001 par value | 1055445 | $0.00 | 2,330,418.0000 | 0 | 82.78% | 0.00% |
| May 5, 2023 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Common Stock, $0.001 par value | 837146 | $0.00 | 1,812,558.0000 | 0 | 85.82% | 0.00% |
| May 5, 2023 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Common Stock, $0.001 par value | 86341 | $0.00 | 145,029.0000 | 0 | 147.12% | 0.00% |
| May 5, 2023 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Pre-funded Warrants to Purchase Common Stock | 2028645 | $0.00 | 2,523,494.0000 | 0 | 409.95% | 0.00% |
| May 5, 2023 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Pre-funded Warrants to Purchase Common Stock | 1609063 | $0.00 | 2,103,912.0000 | 0 | 325.16% | 0.00% |
| May 5, 2023 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Pre-funded Warrants to Purchase Common Stock | 165950 | $0.00 | 660,799.0000 | 0 | 33.54% | 0.00% |
| May 5, 2023 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Warrants to Purchase Common Stock | 3084090 | $0.00 | 3,239,554.0000 | 0 | 1983.80% | 0.00% |
| May 5, 2023 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Warrants to Purchase Common Stock | 2446209 | $0.00 | 2,601,673.0000 | 0 | 1573.49% | 0.00% |
| May 5, 2023 | Eledon Pharmaceuticals, Inc. | $ELDN | BVF PARTNERS L P/IL | TenPercentOwner | P | Warrants to Purchase Common Stock | 252291 | $0.00 | 407,755.0000 | 0 | 162.28% | 0.00% |
| Jan. 19, 2023 | Cullinan Therapeutics, Inc. | $CGEM | BVF PARTNERS L P/IL | TenPercentOwner | J | Series A Convertible Preferred Stock | 350000 | $0.00 | 350,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 19, 2023 | Cullinan Therapeutics, Inc. | $CGEM | BVF PARTNERS L P/IL | TenPercentOwner | J | Common Stock | 2600000 | $0.00 | 392,808.0000 | 0 | 86.87% | 0.00% |
| Jan. 19, 2023 | Cullinan Therapeutics, Inc. | $CGEM | BVF PARTNERS L P/IL | TenPercentOwner | J | Common Stock | 3500000 | $0.00 | 558,854.0000 | 0 | 86.23% | 0.00% |
| Jan. 19, 2023 | Cullinan Therapeutics, Inc. | $CGEM | BVF PARTNERS L P/IL | TenPercentOwner | J | Series A Convertible Preferred Stock | 30000 | $0.00 | 30,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 19, 2023 | Cullinan Therapeutics, Inc. | $CGEM | BVF PARTNERS L P/IL | TenPercentOwner | J | Series A Convertible Preferred Stock | 260000 | $0.00 | 260,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 19, 2023 | Cullinan Therapeutics, Inc. | $CGEM | BVF PARTNERS L P/IL | TenPercentOwner | J | Common Stock | 300000 | $0.00 | 64,161.0000 | 0 | 82.38% | 0.00% |
| Jan. 12, 2023 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Common Stock, $0.0001 par value | 2985 | $31.24 | 2,752,442.0000 | 53,933,229 | 0.11% | 0.01% |
| Jan. 11, 2023 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Common Stock, $0.0001 par value | 10961 | $29.89 | 2,749,457.0000 | 53,933,229 | 0.40% | 0.02% |
| Jan. 11, 2023 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Common Stock, $0.0001 par value | 11149 | $29.89 | 2,130,193.0000 | 53,933,229 | 0.53% | 0.02% |
| Jan. 12, 2023 | Kymera Therapeutics, Inc. | $KYMR | BVF PARTNERS L P/IL | Other | P | Common Stock, $0.0001 par value | 15912 | $31.24 | 2,146,105.0000 | 53,933,229 | 0.75% | 0.03% |